Here’s an idea: Let hospitals make CAR-Ts of their own
The process of CAR-T cancer therapy involves collecting a patient’s T cells, shipping them off to a drug company for genetic engineering, and then bringing them back to the original hospital for treatment. In the name of speed and affordability, why not cut out the middleman?
A patient advocate and two cancer doctors propose just that. As it stands, a dose of CAR-T costs more than $400,000 and takes up to six weeks to make. That, according to the authors, is solely because drug companies are involved. If hospitals could do the genetic engineering in-house — something the top medical centers can do — the price would come down, and potentially curative cancer treatment would be more widely available.
“We took a fork in the CAR-T road a few years back and went the wrong way,” the authors write.
Read more.
A patient advocate and two cancer doctors propose just that. As it stands, a dose of CAR-T costs more than $400,000 and takes up to six weeks to make. That, according to the authors, is solely because drug companies are involved. If hospitals could do the genetic engineering in-house — something the top medical centers can do — the price would come down, and potentially curative cancer treatment would be more widely available.
“We took a fork in the CAR-T road a few years back and went the wrong way,” the authors write.
Read more.
No hay comentarios:
Publicar un comentario